(Q44776902)

6 December 2017

Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism (English)

1 reference

6 December 2017

0 references

1 reference

congestive heart failure

1 reference

6

Johann Bauersachs

1 reference

6 December 2017

Andreas Schäfer

1

1 reference

6 December 2017

Daniela Fraccarollo

2

1 reference

6 December 2017

Piet Tas

3

1 reference

6 December 2017

Isabel Schmidt

4

1 reference

6 December 2017

Georg Ertl

5

1 reference

6 December 2017

1 March 2004

1 reference

European Journal of Heart Failure

6 December 2017

1 reference

6 December 2017

6

1 reference

6 December 2017

2

1 reference

6 December 2017

151-159

1 reference

Endothelium-dependent vasodilation is attenuated in patients with heart failure

6 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Endothelial function in chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Endothelial dysfunction: from physiology to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Prevention of endothelial dysfunction in heart failure by vitamin E: attenuation of vascular superoxide anion formation and increase in soluble guanylyl cyclase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Angiotensin-Converting Enzyme Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Chymase-dependent angiotensin II forming systems in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Angiotensin-converting enzyme inhibition and endothelin antagonism for endothelial dysfunction in heart failure: mono-or combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure: monotherapy versus combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Cardioprotection by long-term ET(A) receptor blockade and ACE inhibition in rats with congestive heart failure: mono- versus combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Physiological mechanisms regulating the expression of endothelial-type NO synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

TCV-116 stimulates eNOS and caveolin-1 expression and improves coronary microvascular remodeling in normotensive and angiotensin II-induced hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

The renin-angiotensin system and experimental heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Aorta and Skeletal Muscle NO Synthase Expression in Experimental Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2003.10.009

10.1016/J.EJHEART.2003.10.009

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference